A Houston entrepreneur is creating a fun and educational platform for children that helps to preserve their heritage. Photo by Kelly Sikkema/Unsplash

Theoharis Dimarhos grew up in a family determined to follow tradition. As a child, his mother serenaded him with old Greek folk songs he still remembers, and his parents made speaking Greek a rule of the house. Dimarhos lived the immigrant family experience, and now he's developed a modern way to preserve pass down culture to the masses.

"My parents came from Greece in 1981, and in typical fashion, they didn't have much and didn't speak the language at all," says Dimarhos, who was born in Cleveland, Ohio. Living the first-generation American experience, he watched his parents work tirelessly to provide for the family and maintain their Greek culture in America.

Dimarhos did get his own immigrant story when his parents decided to move back to Greece when he was 7. After assimilating to Greece, he traveled back to the United States for college, where he learned to readjust once more.

"I kind of got that immigrant experience a couple of times," he says.

While Dimarhos grew up surrounded by his own heritage, he began to realize that "our native cultures were destined to fade if there wasn't a more modern way for children and our little siblings to learn more about their roots."

When talking with his friends from other countries outside of Greece, a general consensus grew: without modern learning, family heritage would slip away.

Enter: Ellis, an app that helps children connect to their culture. The app includes Greek songs, fables, mythology, history, and language.

Named after Ellis Island, a gateway into the United States for so many immigrants in history, Ellis nurtures Greek tradition in a way that caters to children through technology.

"I've always seen [Ellis Island] as a monument of courage to chase your dreams. . .people came and built this country, but also never forgot where they came from."

Interactive technology is becoming a large part of early childhood education, especially during COVID-19, as more families are at-home with children learning virtually. Children are the targets of over 80 percent of the top-selling paid apps in the education category of the iTunes store, according to a published analysis by Carly Shuler in 2012.

Dimarhos and his wife are deeply tied to their Greek heritage, and hope to pass that history and appreciation to their own children once they start a family.

"We wanted to make sure that there was a 21st century way for us and for our children to learn that goes beyond books," he says. "Something that's a little more immersive and fun — fun is very important — and educational."

Ellis is currently being beta tested with a group of 200 active users within the Greek community. The app, which targets ages 0-8, rolls out weekly content to parents.

"I'm receiving texts from friends who are parents begging me to put more content out because they need something to keep their children occupied," says Dimarhos. "Not only are regular schools closed, but cultural schools that are offered by the community are also closed and struggling to open back up."

Time spent on the app can be as short as five minutes and stretch into hours of learning time.

"The goal is always for children to pick up little phrases and words each time they listen," explains Dimarhos.

The stories and songs are all audio-based, tying into activities like waking up, eating breakfast, and bathtime.

"There's something magical about tying in an audio story or song with everyday tasks for kids," says Dimarhos.

Dimarhos parents see the app as "the next step of passing down the torch of our culture," he says.

"They tried to do it with the tools that they had for myself and my sister. . .We're trying to do the exact same thing that they did and their parents did, just with the tools that technology offers us," he says.

Dimarhos, who previously worked in economic development in Austin, had his first experience with startups when his former boss gave him a chance to work with his international accelerator for startups.

"I got my opening into the tech world through the international accelerator and seeing amazing immigrant founders create jobs and strive to do great things in America," he shares.

"Quite honestly, a startup that celebrates different cultures couldn't have a better home than in Houston," he says, noting the massive immigrant population and variety of cultures in the city.

In Dimarhos' own life, he's come across immigrants as well as first and second generation Americans who wish to preserve their own cultures.

"They've wished there was a more modern way to have access to those resources," he explains.

In the future, Dimarhos intends to quickly broaden the app to "launch in every immigrant community in the United States and around the world."

Connecting to cultural roots is something Dimarhos feels is "sacred" to immigrant families.

"It's something that you have the obligation from your parents as they give you everything for you to succeed in life. You kind of carry that obligation to carry that torch and pass it on to your children and their children," he explains.

"We grow up with that and the vision and the mission is just to create something that makes that a little bit easier to keep our cultures alive. I honestly think it's part of what makes this country great," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

Houston billionaire Tilman Fertitta nominated as ambassador to Italy

foreign affairs

Houston billionaire and Rockets owner Tilman Fertitta has been nominated to serve as the United States ambassador to Italy, according to U.S. President-elect Donald Trump.

On Saturday, Trump sent the following statement via Truth Social Post:

"I am pleased to announce that Tilman J. Fertitta has been nominated to serve as the United States Ambassador to Italy. Tilman is an accomplished businessman, who has founded and built one of our Country's premier entertainment and real estate companies, employing approximately 50,000 Americans. Tilman has a long history of giving back to the community through numerous philanthropic initiatives, which include children's charities, Law Enforcement, and the medical community. Additionally, Tilman is the longest serving Chairman of the Board of Regents for the University of Houston. He also owns the Houston Rockets Basketball Team. Congratulations to Tilman, and his remarkable family!"

Fertitta, 67, also is the chairman, CEO, and president of Landry's Inc. and the chairman of the University of Houston's board of regents.

"It is an honor to be nominated to serve my country as ambassador to Italy and I look forward to the process ahead. Italy is such an extraordinary country with its wonderful people, culture, and history and its strategic importance to The United States of America," Fertitta said.

---

Read the full story on CultureMap's news partner, ABC13.com.

Houston biotech biz to merge with public co., set local HQ

big deal

Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters.

Tvardi is a clinical-stage biopharmaceutical company that focuses on the development of novel, oral, and small molecule therapies that target STAT3 to treat fibrosis-driven diseases. Tvardi will merge with a wholly owned subsidiary of Cara.

Once complete, the pre-merger Cara Therapeutics stockholders are expected to own approximately 17 percent of the combined company and pre-merger Tvardi Therapeutics investors are expected to own 83 percent of the combined company. Prior to adjustment from the issuance of the shares in the recently completed Tvardi financing and assuming Cara, which went public in 2014, has net cash at closing of between $22.9 million and $23.1 million with the percentage of the combined company that pre-merger Cara stockholders and pre-merger Tvardi stockholders will own upon the closing of the merger, which is subject to further adjustment if Cara’s net cash balance falls outside of the range.

“As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs,” Imran Alibhai, CEO of Tvardi Therapeutics, says in a news release.

Also, Tvardi has completed an approximately $28 million private financing from a syndicate of new and existing institutional investors. With the cash from both companies at closing and the proceeds of this financing, the post-merger company plans to have cash to fund its operating expenses and capital expenditure requirements into the second half of 2026.

“I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases,” Alibhai continues.

In 2021, Tvardi emerged from stealth and closed a $74 million series B funding round led by New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.